NCT03216473View on ClinicalTrials.gov

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm

PHASE3CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

May 25, 2016

Primary Completion Date

March 17, 2017

Study Completion Date

July 4, 2017

Conditions
Essential Blepharospasm
Interventions
DRUG

Neuronox

Clostridium Botulinum Toxin A 100 U

DRUG

Botox

Clostridium Botulinum Toxin A 100 U

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT03216473 - Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm | Biotech Hunter | Biotech Hunter